Keith W. Cooper
Executive-in-Residence @ Vimac Ventures
Boston, United States
Keith W. Cooper is a startup investor at Vimac Ventures in Boston. Keith is a Venture Partner of VIMAC, joining the Firm in September, 2000. Keith has been associated with the VIMAC portfolio since 1996 as the CEO of FaxNet, one of VIMAC's most successful portfolio companies. After working with the VIMAC team over an 8 year period as CEO of two successful portfolio companies, he was very impressed withthe the culture, the people and their investment strategy. He then decided to affiliate himself with the Firm as a Venture Partner. In this role, he advise the partners on deal selection and company management. He also sit on several Boards of VIMAC portfolio companies where his industry knowledge can add value.
Last updated:
For AI agents: llms.txt
About Vimac Ventures
VIMAC's investing model is founded on two core principles—respect for the entrepreneur, and humble acceptance that nobody has seen the future. New business creation is essentially a collaborative enterprise where success requires continuous learning and broad-based sharing of innovative ideas.Based in Boston, they deploy capital inearly-stage companies located in the eastern U.S. and Canada. Today, they have two separate investment teams—one focused on early stage ventures in IT/Adv.Materials technologies and the other focused on life sciences.To date, VIMAC investments have led to the creation of over 20 successful companies that continue to generate business innovations in IT, communications, and Internet technologies. These investments today account for over $2 billion in market value. The fund seeks to make about five new investments each year. A new investment typically goes into a Series A or Series B round with adequate reserves to support subsequent funding until the company exits via a trade sale or an IPO. Over its lifetime, a company is likely to receive $5 million to $15 million from the fund. The life sciences team makes investments from the VIMAC Milestone Medica in early stage biotechnology and medical device companies.They lead or co-lead most investments and their managers play a very active role on portfolio companies’ Boards of Directors. Often, they invest in a company's first institutional round of funding and maintain support throughout the company’s lifecycle. Along the way, they maintain a close working relationship with the management team, helping them refine business plan, build go-to-market strategies, enhance capital efficiency, find early customers and partners, and grow the business.
Vimac Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David Marcus
Managing Director, Life Sciences
|
|||
Douglas G. Redding
Executive-in-Residence
|
|||
|
Keith W. Cooper
Executive-in-Residence
|
|||
R. Dana Ono, PhD
Managing Director
|
|||
Robert C. Roeper
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
FAQ
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
